• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$3.77 -$0.10 (-2.58%)

REAL-TIME: Last trade at

Pain Therapeutics, Inc.

NASDAQ:PTIE

Market Correlation: From Record Highs to the Lowest in 25 Years

Durect Investors Feel the Pain

Wall Street's Wrong About These Stocks

3 Stocks Stopping the Presses

A Less Painful FDA Decision

Stock Futures Drift Higher as Traders Eye Greek Developments

Pain Therapeutics: FDA Says Pain Killer Had Inconsistent Results

Oracle, Micron Tech and Pfizer light up StockTwits

Stocks falter in early trading

FDA Rejects Drug Application For Pain Killer From Pfizer, Pain Therapeutics

Stocks Slump, But Off Lows, as Investors Eye Revised GDP Data; Commodities in Red

Mid-Day Update: Stocks Lower; Earnings, GDP Data Disappoint

Pain Therapeutics, Durect Shares Plunge on Pain Drug Rejection

Acura Surges on PainkIller Approval

Previewing a Pair of Pain Drug FDA Decisions

Mid-Day Update: Stocks Sagging as Investors Eye Earnings, Fed Meeting

Stocks Lower Despite Positive Housing News; Market Awaits Big Earnings Results, Fed Policy Meeting

25 Small Caps With Sales and EPS Declining in 2012

Analyst Calls: APOL, CEPH, DELL, GCI, GOLD, KSS, LEN, PEET, PM ...

Pain Therapeutics' Opium for the Masses

Pharmaceutical Companies Reformulate Pain Products: How Investors Can Benefit

Pain Therapeutics: Optimistic Indicators, Large Upside Potential

King Pharma Resubmits FDA Application For Remoxy

Pfizer Is Not Paying a Ransom for King

Pfizer's Osteoarthritis Drug Runs Into Unique Roadblock